Ágnes Prókai1, Rózsa Csohány1, Erna Sziksz1,2, Domonkos Pap1, Leonóra Balicza-Himer1, Szilvia Boros1, Balázs Magda3, Ádám Vannay1,2, Katalin Kis-Petik4,5, Andrea Fekete1, János Peti-Peterdi6,7, Attila J Szabó1,2. 1. First Department of Pediatrics, Semmelweis University, Budapest, Hungary. 2. MTA-SE, Pediatrics and Nephrology Research Group, Budapest, Hungary. 3. Institute of Organic Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary. 4. Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary. 5. MTA-SE Molecular Biophysics Research Group, Budapest, Hungary. 6. Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA. 7. Department of Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA.
Abstract
BACKGROUND: Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allograft rejection. Calcineurin inhibitors are known to be nephrotoxic. However, the precise mechanism of nephrotoxicity is not fully understood. In this study, we investigated the in vivo effects of CNIs on the local renal renin-angiotensin system in the collecting duct (CD). METHODS: Three-week-old mice were treated with either vehicle, CyA (2 mg/kg per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks. Serum creatinine was measured. Renin and vascular endothelial growth factor (VEGF) contents in CD were evaluated with flow cytometry and multiphoton microscopy. The diameter of vessels was assessed with multiphoton microscopy, and the amount of renal collagen was determined by real-time polymerase chain reaction and Masson staining. RESULTS: The elevated level of serum creatinine in CNI groups was abolished by Aliskiren. Flow cytometric analysis found elevated renin content in principal cells, which was prevented by Aliskiren. This result was further confirmed with multiphoton microscopy. The VEGF content in CD correlated with reduced capillary diameter and with the formation of fibrotic islands. CONCLUSIONS: Calcineurin inhibitors induce production of renin in the CD that may contribute to decreased renal blood flow. In turn, CD responds with increased VEGF production, resulting in disproportional vessel growth, further worsening the local hypoxia and striped fibrosis surrounding the CDs. Aliskiren, a direct renin inhibitor blocks these effects and improves CNI-induced nephropathy by decreasing renin production in the CDs. Our data suggest that Aliskiren may be used for the prevention of CNI nephrotoxicity.
BACKGROUND:Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allograft rejection. Calcineurin inhibitors are known to be nephrotoxic. However, the precise mechanism of nephrotoxicity is not fully understood. In this study, we investigated the in vivo effects of CNIs on the local renal renin-angiotensin system in the collecting duct (CD). METHODS: Three-week-old mice were treated with either vehicle, CyA (2 mg/kg per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks. Serum creatinine was measured. Renin and vascular endothelial growth factor (VEGF) contents in CD were evaluated with flow cytometry and multiphoton microscopy. The diameter of vessels was assessed with multiphoton microscopy, and the amount of renal collagen was determined by real-time polymerase chain reaction and Masson staining. RESULTS: The elevated level of serum creatinine in CNI groups was abolished by Aliskiren. Flow cytometric analysis found elevated renin content in principal cells, which was prevented by Aliskiren. This result was further confirmed with multiphoton microscopy. The VEGF content in CD correlated with reduced capillary diameter and with the formation of fibrotic islands. CONCLUSIONS: Calcineurin inhibitors induce production of renin in the CD that may contribute to decreased renal blood flow. In turn, CD responds with increased VEGF production, resulting in disproportional vessel growth, further worsening the local hypoxia and striped fibrosis surrounding the CDs. Aliskiren, a direct renin inhibitor blocks these effects and improves CNI-induced nephropathy by decreasing renin production in the CDs. Our data suggest that Aliskiren may be used for the prevention of CNI nephrotoxicity.
Authors: Andreas Linkermann; Jan-Ole Heller; Agnes Prókai; Joel M Weinberg; Federica De Zen; Nina Himmerkus; Attila J Szabó; Jan H Bräsen; Ulrich Kunzendorf; Stefan Krautwald Journal: J Am Soc Nephrol Date: 2013-07-05 Impact factor: 10.121
Authors: J Julien; D Farge; C Kreft-Jais; T T Guyene; P F Plouin; D Houssin; A Carpentier; P Corvol Journal: Transplantation Date: 1993-10 Impact factor: 4.939
Authors: B D Myers; R Sibley; L Newton; S J Tomlanovich; C Boshkos; E Stinson; J A Luetscher; D J Whitney; D Krasny; N S Coplon Journal: Kidney Int Date: 1988-02 Impact factor: 10.612
Authors: Can Li; Chul Woo Yang; Wan Young Kim; Ju Young Jung; Jung Ho Cha; Yong Soo Kim; Jin Kim; William M Bennett; Byung Kee Bang Journal: Am J Physiol Renal Physiol Date: 2002-10-22
Authors: Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner Journal: Clin J Am Soc Nephrol Date: 2019-12-13 Impact factor: 8.237
Authors: Sonal Singh; Caitrin W McDonough; Yan Gong; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; John G Gums; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson Journal: Sci Rep Date: 2019-11-21 Impact factor: 4.379